Quick Search 
Drugs of Today
Register or sign in

  
 
  
Drugs Today 2007, 43(6): 423
ISSN 1699-3993
Copyright 2007 Clarivate Analytics
CCC: 1699-3993
DOI: 10.1358/dot.2007.43.6.1067341
 
 
Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: Beta-amyloid(1-42), tau, phospho-tau-181 and total protein
Marksteiner, J., Hinterhuber, H., Hinterhuber, C.
 
 
Alzheimer's disease is a chronic progressive neurodegenerative disease and it is the most prevalent type of dementia. Diagnostic means, including neuroimaging methods, are continuously improving. Nevertheless, it is still a challenge to increase the sensitivity and specificity of a diagnosis of Alzheimer's disease. Two diagnostic areas are especially challenging: first, differentiating early stages of Alzheimer's disease from mild cognitive impairment and normal aging; and second, increasing diagnostic specificity especially when similar clinical symptoms are shared by various types of dementia. To date, the analysis of beta-amyloid(1-42), total tau and phospho-tau-181 from cerebrospinal fluid (CSF) are the best biological markers to diagnose Alzheimer's disease and differentiate it from other forms of dementia with a high reliability and validity. This article reviews the use of CSF biomarkers and of putative blood-related markers.


Full Text: HTMLPDF 
 
  



© Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy